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Apoptosisman papillomavirus (HPV) 16 E6, exempliﬁed by the Asian–American variant
Q14H/H78Y/L83V, were shown to be more prevalent than E6 prototype in progressing lesions and cervical
cancer. We evaluated functions relevant to carcinogenesis for the E6 variants L83V, R10/L83V and Q14H/
H78Y/L83V as well as the prototype in a model of human normal immortalized keratinocytes (NIKS). All E6
expressing NIKS equally abrogated growth arrest and DNA damage responses. Organotypic cultures derived
from these keratinocytes demonstrated hyperplasia and aberrantly expressed keratin 5 in the suprabasal
compartment. In contrast, differentiation and induction of apoptosis varied. The E6 variant rafts expressed
keratin 10 in nearly all suprabasal cells while the prototype raft showed keratin 10 staining in a subset of
suprabasal cells only. In addition, E6 variant NIKS expressing R10G/L83V and Q14H/H78Y/L83V were more
prone to undergo cell-detachment-induced apoptosis (anoikis) than NIKS expressing E6 prototype. The
combined differentiation and apoptosis pattern of high-risk E6 variants, especially of Q14H/H78Y/L83V, may
reﬂect a phenotype beneﬁcial to carcinogenesis and viral life cycle.
© 2008 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Persistent infection with oncogenic human papillomavirus (HPV)
types is a major risk factor in the development of a high-grade cervical
lesion and progression to cancer. Among the HPV types associated with
cervical cancer, HPV16 is the most prevalent type (Zur Hausen, 1996,
2002). The properties governing viral persistence are largely unknown
(Ferenzy and Franco, 2002). Accumulating epidemiological data suggest
that viral genome variants, which diverge by about 2% within a given
type and which differ geographically (Yamada et al., 1997), could
contribute to viral pathogenicity presumably by altering its carcinogenic
potential and immunogenicity (Bernard, 2005, Bernard et al. 2006). The
association between HPV16 variants with viral persistence and progres-
sion of cervical neoplasia was proven in numerous epidemiological
studies (Berumen et al., 2001, del Refugio Gonzales-Losa et al., 2004;
Grodzki et al., 2006; Hildesheim et al., 2001; Lee et al., 2008;
Londesborough et al., 1996; Picconi et al., 2003; Sathish et al., 2005;
Sichero et al., 2007; Villa et al., 2000; Xi et al., 1995, 1997, 2006). In
contrast, the Europeanprototype HPV16, based on the Seedorf sequence
(Seedorf et al., 1985), was linked to viral clearance and lesion regression
(Grodzki et al., 2006). Another type of evidence indicated that the E6-NC-ND license.open reading frame (ORF), preferentially over that of other HPV ORFs, is
evolving under Darwinian selection (Chen et al., 2005). These ﬁndings
were corroborated by our extensive surveys of E6, E7, L1, L2, E2 and the
LCR of HPV16, where we showed that merely E6 variants are associated
withdisease development (Grodzki et al., 2006;Kämmeret al., 2002; Lee
et al., 2008; Zehbe et al., 1998a,1998b, 2001a, 2001b). Collectively, these
ﬁndings underline the biological relevance of E6 variants and provide a
strong justiﬁcation for deﬁning the underlying differences between E6
variants that contribute to their differential role in human disease.
To date, a limited number of investigations by us and others indicate
that E6 variants confer differences in biochemical activities of E6
(Asadurian et al., 2007; Conrad-Stoppler et al., 1996; Lichtig et al., 2006)
as well as in differentiation (Conrad-Stoppler et al., 1996; Lichtig et al.,
2006) and transformation properties (Chakrabarti et al., 2004) of
human epithelial cells in tissue culture compared to the prototype
HPV16 E6. Cellular homeostasis is ﬁnely tuned by controlling prolifera-
tion, differentiation and apoptosis. An abrogation or imbalance of these
entities is implicated in carcinogenesis. To date, no study has addressed
together all of these aspects of tissue homeostasis in the context of
HPV16 E6 variants and cervical cancer. Herein, we carried out such a
study using a human keratinocyte cell line that can undergo a normal
cellular differentiation program when placed in organotypic culture.
Noted differences in the current study pertaining to perturbation of
differentiation and modulation of apoptosis may explain data obtained
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Results
Gene transfer of HPV16 E6 prototype and E6 variants into normal
immortalized keratinocytes (NIKS)
Individual E6 genes (prototype or variants) were cloned into the
retroviral vector LXSN and transduced into normal immortalized
keratinocytes (NIKS) (Allen-Hoffmann et al., 2000). After selection
with G418, each E6 expressing culturewas subjected to PCR followed by
sequencing (Zehbe et al., 1998a) to conﬁrm that only the expected
variant was expressed by the recipient NIKS cell line. All E6 variants and
the prototypewere similarly expressed at themRNA and protein level as
determined by quantitative real time polymerase chain reaction (qRT-
PCR) as well as by Western blotting using a monoclonal mouse-anti E6
antibody (clone 6F4; Lagrange et al., 2005) (Fig. 1). To determine the
sub-cellular localization of the E6 proteins by immunoﬂuorescence the
6F4 clone was not applicable. Instead, an anti-HA tag antibody yielded
speciﬁc, mostly nuclear and some cytoplasmic staining. Taken into
consideration that E6 interacts with a wide variety of host cellular
proteins both cellular locations would be expected.
HPV16 E6 variants and prototype similarly abrogate growth arrest and
inhibit elevation of p53 induced by actinomycin D
The ability to inhibit growth arrest and to abrogate DNA damage
responses induced by p53 is crucial during HPV-associated carcino-
genesis and thought to be largely mediated by high-risk HPV E6
proteins (Kessis et al., 1993). The G1 checkpoint requires functional p53.Fig. 1. Gene expression of HPV16 E6 variants and prototype in NIKS as deﬁned by quantitative
For qRT-PCR, values represent raw qRT-PCR delta Ct values and standard deviations. cDNA i
System (Bio-Rad, Mississauga, ON, Canada) as previously described (DeCarlo et al., 2008). For
E6 protein. The micrograph shows immunoﬂuorescence against the HA-tag epitope. E6-speLow levels of actinomycin D (AD) cause strandbreaks by interferingwith
topoisomerases resulting in growth arrest predominantly in G1 in
normal cells (Trask and Muller, 1988). The capacity of the E6 protein to
target p53 for degradation in vivo was shown to correlate with their
ability to abrogate AD-induced growth arrest (Foster et al., 1994). We
examined the ability of E6 prototype and E6 variants to override growth
arrest and to reduce p53 levels induced by AD. The distribution of cells in
the G1, S and G2/M phases and the G1/S ratios were determined with
and without treatment of 0.5 nM AD for 24 h (Figs. 2A–B). Treatment of
control vector NIKS resulted in growth arrest as evidenced by an
increase of cells in G1 phase and a reduction of cells in S phase (Fig. 2A).
The G1/S ratio differed signiﬁcantly between treated and untreated cells
(Fig. 2B). In contrast, no signiﬁcant change in G1/S ratio was observed in
E6-transduced NIKS indicating that all E6 variant and the prototype cell
lines could overcome the growth arrest induced by AD (Fig. 2B). In the
empty vector cells, the ratio increased ﬁve-fold, while it stayed close to 1
in the E6-transduced NIKS in the presence of AD (Fig. 2B). In addition, all
E6 cultures demonstrated an increased proportion of cells in G2/M after
AD treatment (not signiﬁcant; Fig. 2A). Consistent with the above
results, E6 variant and prototype but not empty vector NIKS signiﬁcantly
lowered the steady-state levels of p53 and were able to prevent the
elevation of p53 after AD treatment as deﬁned by ELISA and Western
blot (Fig. 3). These results suggest that the E6 protein can accommodate
amino acid changes without signiﬁcantly perturbing the activity of this
protein in degrading p53 and overriding the growth arrest.
HPV16 E6 variants and prototype selectively alter keratinocyte
differentiation induced in organotypic keratinocyte raft cultures
Stratiﬁed squamous epithelium consists both of a poorly differ-
entiated, proliferating basal compartment and a quiescent terminallyreal time polymerase chain reaction (qRT-PCR), Western blot and immunoﬂuorescence.
nput concentrations were determined using the Experion™ Automated Electrophoresis
Western blot, input of 120 μg of total protein showed a band of the expected size for each
ciﬁc staining appears in green.
Fig. 2. Cell cycle proﬁle of HPV16 E6 prototype and variants. Datawith andwithout actinomycin D (AD) treatment (0.5 nM for 24 h) are shown. The distribution of cells in G1, S and G2/
M phases obtained by ﬂow cytometry is demonstrated in (A). Differences in G1/S ratio are depicted in (B). Mean values of at least three independent experiments are presented as
average (mean) values±standard deviation (SD). Signiﬁcance was tested by a one-way ANOVA test. A P value of b0.05 was considered signiﬁcant.
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in these compartments are tightly regulated by several transcription
factor families such as C/EBP, AP-2 and p63 (Koster and Roop, 2007)
and are characterized by intermediate ﬁlament structures denoted
keratins. While keratin pairs K5 and K14 are exclusively transcribed inFig. 3. p53 levels of HPV16 E6 prototype and variants. ELISA showing the remaining units of p5
values of at least three independent experiments are presented as average (mean) values±s
b0.05was considered signiﬁcant. The correspondingWestern blot showed only p53-speciﬁc b
amount of p53 was increased approximately threefold as seen with ELISA.the basal compartment, K1 and K10 are selectively expressed in the
suprabasal compartment. To evaluate the HPV16 E6 variants in
altering differentiation, we monitored E6-transduced NIKS when
grown in organotypic raft cultures, which permits the normal
differentiation/stratiﬁcation program of human keratinocytes.3 quantiﬁed according to the number of cells after AD treatment (0.5 nM for 24 h). Mean
tandard deviation (SD). Signiﬁcance was tested by a one-way ANOVA test. A P value of
ands for empty vector NIKS. P53-negative results are not shown. After AD treatment the
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ences in histological architecture. The raft culture obtained from NIKS
transduced with the empty vector showed ordered stratiﬁcation and
epithelial thickness comparable to normal skin as previously
described (Allen-Hoffmann et al., 2000). A layer of undifferentiated
basal cells and several layers of suprabasal cells could be distinguished
(Fig. 4A). NIKS transduced with the E6 variants strongly deviated from
the normal histology. All cultures were hyperplastic with abnormal
stratiﬁcation, showed nuclear atypia and lacked polarity. The basal
layer did not substantially differ from suprabasal layers in cell size or
nuclear appearance. Nuclei were present in all layers but mitotic
ﬁgures, usually observed in epithelial dysplasia, were absent (Fig. 4A).
Next, we performed immunoﬂuorescence using antibodies against
basal cell keratins K5 and against the suprabasal cell differentiation
marker K10 to examine whether K5 and K10 expression varied
amongst E6 variants and prototype raft cultures (Fig. 4A). In the vector
control NIKS, expression of the basal cell type markers K5 was
conﬁned to the basal cell compartment showing staining in basal and
parabasal cells. K10 was uniformly expressed in suprabasal cells of the
NIKS control raft culture. Thus, control rafts demonstrated a
complementary staining pattern of differentiation markers mostly
reminiscent of normal skin. In contrast, the rafts expressing E6 variant
or prototype proteins exhibited perturbed epithelial differentiation
(Fig. 4A). K5 was uniformly expressed in all layers within the raft
epithelium, basal and suprabasal, independent of the E6 subtype. The
average intensity of K5 staining in all E6 rafts was signiﬁcantly higher
than that of the vector (Fig. 4B). The R10G/L83V culture exhibited the
highest staining and compared to vector, prototype and Q14H/H78Y/
L83V rafts the difference was statistically signiﬁcant. Two differentia-
tion patterns based on suprabasal cell type marker K10 were
identiﬁed: one with uniform staining and one with sporadic staining
within the suprabasal compartment (Fig. 4A). The ﬁrst category
included the three E6 variants with K10 expressed in almost all cells
within the suprabasal compartment. The second category contained
the prototype with K10 staining only seen in a subset of cells within
the suprabasal compartment. Overall area intensity of K10 staining in
the suprabasal layer was lower in the prototype, L83V and R10G/L83V
rafts as compared to the empty vector raft, with the difference being
statistically signiﬁcant (Fig. 4B). The Q14H/H78Y/L83V raft showed a
staining intensity comparable to that of the vector. The lowest K10
expression was seen in the prototype raft, which, compared to the
expression intensity of all other rafts, is statistically signiﬁcant.
Collectively, these data suggest that E6 has the ability to abrogate
the differentiation program in organotypic keratinocyte cultures and
that E6 variants and the prototype selectively inﬂuence differentiation
functions.
The ability of HPV16 E6 variants and prototype to modulate apoptosis
induced by cell suspension in semisolid medium differs
When detached from the basal membrane, keratinocytes are
committed to terminal differentiation and eventually to programmed
cell death in vivo. NIKS are permissive for cell-detachment-based
apoptosis (anoikis), which is triggered by the extrinsic death receptor
pathway (Marconi et al., 2004). This cascade can be mimicked in the
laboratory by treating cells with semisolid medium. NIKS were
exposed to serum-free mediummade semisolid with methylcellulose.
Incubation in suspension was carried out for 16 h. This time was
chosen because prior experiments revealed that caspase-3 expression
is highest at this time point (data not shown). Cell density had to be
tightly controlled as it affected the results. NIKS kept in suspension
underwent the signs of apoptosis as determined by annexin V-FITC
labeling and ﬂow cytometry analyses, based on the appearance of
phosphatidylserine in the outer leaﬂet of the cell membrane.
Apoptosis was induced in vector control as well as in E6 transduced
NIKS (Fig. 5). A small fraction, 2.4–5.6%, consisted of early apoptoticcells (annexinV+/PI−) with no signiﬁcant difference in their proportion
among the tested cultures. A larger fraction of cells, 24.3–54.5%, also
stained with propidium iodide (annexinV+/PI+) indicating late
apoptotic cells. With regard to late apoptotic cells, only Q14D/H78Y/
L83V showed statistically signiﬁcant results compared to vector
control cells. Unexpectedly, levels of late apoptotic cells were higher
in NIKS expressing this variant than in control cells. Similar but not
signiﬁcant results were obtained with R10G/L83V. The prototype and
L83V NIKS on the other hand showed lower levels of late apoptotic
cells than control NIKS but this ﬁndingwas not statistically signiﬁcant.
Most importantly, signiﬁcant differences in late apoptotic cell
numbers were seen between E6 prototype and L83V versus R10G/
L83V and Q14D/H78Y/L83V. These ﬁndings indicate that speciﬁc
HPV16 E6 variants sensitize NIKS to suspension-induced extrinsic
apoptosis.
Discussion
In the present study we have dissected the functional signiﬁcance
of three common variants isolated form Scandinavian women and the
E6 prototype in a model of human keratinocytes. While all E6 proteins
tested demonstrated similar abilities to abrogate cell cycle arrest and
DNA damage responses, deregulation of differentiation and apoptosis
were more variable. Note that this is the ﬁrst investigation to compare
the differentiation properties of naturally occurring HPV16 E6 variants
in raft cultures providing a basis for future mechanistic studies. Here,
we chose the model of NIKS because NIKS have the advantage over
primary keratinocytes in that they do not rely upon HPV oncogenes
for their long-term growth and therefore provide advantages in terms
of establishing cell populations that can reproducibly be analyzed in
organotypic culture. HA-tagged E6 proteins used in this investigation
most likely did not impact on the biological activities of E6. For
instance, resistance to apoptosis, altered expression of K10 and
degradation of p53 that had been established for the E6 prototype
protein earlier by other investigators (Filippova et al., 2007; Flores et
al., 1999; Garnett et al., 2006; Scheffner et al., 1990) largely reﬂected
our results obtained for the E6 prototype.
Activation of p53 and induction of p53-mediated growth-arrest are
important cellular responses to DNA damage and disruption of these
responses by E6 is believed to contribute to subsequent accumulation
of genetic changes associated with cervical carcinogenesis (DiMaio
and Liao, 2006; Mantovani and Banks, 2001). Consistent with our
previous studies (Asadurian et al., 2007; Lichtig et al., 2006), we show
that all tested variants were capable of strongly reducing steady-state
levels of p53 in NIKS. The present study also shows that all variants
were able to both suppress the elevation in levels of the p53 protein
and override p53-mediated growth-arrest that normally is induced by
actinomycin D (Kessis et al., 1993). The similarities in the modulation
of DNA damage responses among the E6 variants, both in terms of
suppression of p53 accumulation and overcoming growth arrest,
suggest that these functions of E6 cannot be compromised to initiate
the carcinogenic process.
Expression of high-risk E6 and E7 oncoproteins was previously
shown to induce alteration of keratinocyte differentiation in organo-
typic cultures (Flores et al., 2000; Halbert et al., 1992; Hudson et al.,
1990; McCance, et al., 1988; Woodworth et al., 1992). The contribution
of the individual proteins to this altered phenotype has not been
completely deﬁned. In several studies where E6 and E7 were
expressed in the context of the whole genome or individually, E7
was found to be the major oncoprotein contributing to disorganized
layer formation, and hyperplasia in organotypic cultures (Flores et al.,
1999, 2000; Halbert et al., 1992; Ueno et al., 2006), whereas in other
studies, a more signiﬁcant contribution of E6 was identiﬁed (Hudson
et al., 1990; Lee and Laimins, 2004). Moreover, HPV16 E6was shown to
inhibit terminal differentiation and stratiﬁcation of primary human
keratinocytes induced by calcium and serum in monolayer cultures
Fig. 4. Keratinocyte differentiation induced in 3D raft cultures. Micrographs including immunoﬂuorescence for basal cell keratin marker K5 (green), suprabasal cell marker K10 (green), the overlay of both and H+E stainings are depicted in (A).
Of note, rafts had been grown three times and sections were cut twice from each set of parafﬁn blocks to ensure reproducibility. Quantiﬁcation diagrams of basal and suprabasal keratins of the above rafts are shown in (B). Calculations of K5 and
K10 levels are shown for each HPV16 E6 genotype and the empty vector control raft as described in Materials and methods. Values of area intensities for K5 and K10 in the basal and suprabasal regions from 4 sections are presented as average











Fig. 5.Modulation of apoptosis by HPV16 E6 prototype and variants. Using ﬂowcytometry early (Annexin V-FITC+/propidium iodide-) and late apoptotic (Annexin V-FITC+/propidium
iodide+), cells were calculated. Mean values of four independent experiments are presented as average (mean) values±standard deviation (SD). Signiﬁcance was tested by a one-way
ANOVA test. A P value of b0.05 was considered signiﬁcant.
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epidermal hyperplasia in transgenicmice (Nguyen et al., 2006; Song et
al., 1999). In the present study, the hyperplastic changes induced by
HPV16 E6 variants and prototype in NIKS organotypic cultures
recapitulated the effect of E6 observed in transgenic mice. In addition,
we demonstrate deregulated expression of squamous cell differentia-
tion proteins of all E6-expressing rafts. All E6 variant proteins and the
prototype led to aberrant K5 expression in suprabasal cells. However,
the variants but not the prototype simultaneously expressed K5 and
K10 in all keratinocytes within the suprabasal compartment (Fig. 4A).
Replication of suprabasal keratinocytes aberrantly co-expressing K5
and K10 due to a premature migration of proliferating keratinocytes
into the suprabasal compartment is a hallmark of early squamous cell
carcinogenesis (Hansen et al., 2000, Huitfeldt et al., 1991; Ruiz et al.,
2004). Interestingly, this phenotype is linked to the E6 variants rather
than the prototype (Flores et al., 1999 and this study) and may reﬂect
an advantage for the variants in promoting carcinogenesis. In addition,
the observed phenotype may impact on the viral life cycle, which is
tightly linked to the differentiation program of the cell and typically
occurs during early carcinogenesis.
Suspension of normal keratinocytes into semisolid medium
induces a rapid and substantial increase in the percentage of cells
expressing suprabasal keratin proteins (Drozdoff and Pledger, 1993),
e.g. of keratin 10 (Zehbe, unpublished data). This trigger also induces
nucleosomal fragmentation, characteristic of apoptosis, in NIKS
(Allen-Hoffmann et al. 2000). Using low calcium and serum-free
semisolid medium, E6 prototype and L83V resisted apoptosis more
than did the vector in the context of the NIKS cell line. Though this is in
concordance with the notion that high-risk E6 proteins restrain
keratinocytes from undergoing apoptosis, the difference was marginal
and not statistically signiﬁcant. Nevertheless both Q14H/H78Y/L83V
and R10G/L83V demonstrated signiﬁcantly higher levels of late
apoptosis than E6 prototype and L83V, which seems unusual but is
not unprecedented. Indeed, CaSki cells (R10G/L83V) more than SiHa
cells (L83V) have been reported to undergo apoptosis when deprived
of cell anchorage (Kikuchi and Yasumoto, 1999). These data indicate
that, under certain circumstances, HPV16 induces rather than inhibits
apoptosis. The differential modulation of apoptosis observed in this
investigation could form a basis for novel and individual treatment
strategies. The biological signiﬁcance of this ﬁnding could be a means
for the virus to release viral particles thereby facilitating persistence
via re-infection of the same host and transmission to new hosts. In line
with this notion is the fact that caspase-3 has been found elevated
during the productive stage of the viral life cycle (Moody et al., 2007).
Additional studies are needed to characterize the process of apoptosis
in terminally differentiating keratinocytes and its role in the HPV life
cycle.
What could the underlying mechanism be for the differential
phenotypes triggered by the various E6 proteins with respect todifferentiation and apoptosis? The E6 oncoprotein targets cellular
proteins through protein–protein interactions, which can result in loss
or gain of function. Differential binding to and altered expression of E6
targets could be the reason for our observations. Possible candidates
are previously reported cellular partners known to interact with E6
prototype such as tumor necrosis factor receptor 1 (Filippova et al.,
2007), Fas-associated death domain protein (Garnett et al., 2006),
caspase-8 (Filippova et al., 2002) and p73 (Park et al., 2001) from the
death receptor pathway as well as histone acetyltransferase p300
(Patel et al., 1999), CREB-binding protein (Huang and McCane, 2002)
and c-Myc (Veldman et al., 2003) involved in transcription during
keratinocyte differentiation. Work exploring this possibility is in
progress.
We postulate that the combined differentiation and apoptosis
characteristics of high-risk E6 variants observed in this study confer a
selective advantage for the virus to persist in the host impacting on its
oncogenic potential. Our data may explain the high prevalence of
certain HPV16 E6 variants in populations and in high-grade cervical
disease worldwide, especially with respect to the Asian–American
variant Q14H/H78Y/L83V (Berumen et al., 2001). Indeed, the risk of
this variant to persist and cause lesion progression was reported to be
20-fold higher than that of prototype E6 (Berumen et al., 2001). While
the current study has addressed certain aspects of deregulating
cellular homeostasis in the presence of different HPV16 E6 proteins,
the underlying mechanisms and pathways will have to be elucidated
in a relevant infectious virus model using full-length HPV16 DNA.
Materials and methods
Human papillomavirus 16 E6 genotypes
We have chosen four HPV16 E6 species, which had previously been
detected in clinical samples from Scandinavian women: the European
species E6 prototype, L83V and R10G/L83V as well as the Asian–
American variant Q14H/H78Y/L83V (Zehbe et al., 1998a, 2001a,
2001b).
Cloning of the E6 genotypes
Patient samples with the respective E6 variant were PCR-ampliﬁed
with primers including the restriction site for EcoRI or BglII (under-
lined): 5′-GTTCATGTTTCAGGACCCACAG-3′ and 5′-AGATCTCAGCT-
GGGTTTCTCTACGTGT-3′ as described earlier (Lichtig et al. 2006). The
E6 genes were cloned into the LXSN vector with the hemagglutinin
(HA) tag sequence at the C-terminus followed by a stop codon to
facilitate the delivery into the amphotropic packaging cell line
Phoenix (Morgenstern and Land, 1990). The HA-tag approach was
chosen for the current study because it was the only means to detect
variant E6 proteins by immunoﬂuorescence.
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High titer retroviral supernatants were generated by transient
transfection of the Phoenix cell line (amphotropic virus). One day
before transfection, 5×105 Phoenix cells were plated onto 10 cm
Petri dishes. They were cultured in 10 ml DMEM supplemented with
10% FCS, 1% penicillin/streptomycin and 1% L-glutamine. Sub-
conﬂuent cells were transfected with 10 μg of the empty or with
the recombinant retroviral vectors by calcium phosphate precipita-
tion according to the manufacturer's instructions (Clonetech,
Heidelberg, Germany). Before transient transfection, 2.5 mM clor-
oquine in fresh medium was added to the cells for 15 min followed
by the transfection cocktail. After 8 to 10 h the monolayer was
washed with PBS and the medium was changed to DMEM without
chloroquine. At 24 h post transfection, the medium was changed
again and the viral supernatant was collected 24 h later. The virus-
containing supernatant with the addition of 4 μM polybrene was
immediately used to infect NIKS that were grown to 50% conﬂuency
in the presence of mitomycin-treated Swiss mouse 3T3 ﬁbroblasts
(CCL-92 from ATCC, Manassas, VA, USA) as previously described
(Morgenstern and Land, 1990). After 3 h of incubation with the viral
stock, fresh medium was added at the same volume as the viral
supernatant. NIKS were selected in medium containing 150 μg G418/
ml 48 h post infection.
Quantiﬁcation of E6 expression
To ensure that equal amounts of E6 are expressed in each E6
culture E6 mRNA was quantiﬁed by qRT-PCR using TaqMan®
chemistry and the ABI 7500 instrument (Applied Biosystems, Foster
City, CA, USA) as previously described (DeCarlo et al., 2008). HPV16 E6
speciﬁc primers were obtained as Custom TaqMan® Gene Expression
Assays from Applied Biosystems.
Western blot analysis
To determine the levels of HPV16 E6 in each of the E6 variant
cell lines, cells were trypsinized and subsequently lysed in ice-cold
HNTG lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1.1% Triton
X-100, 1 mM EGTA, 10% glycerol, 1 mM PMSF, 1× PIC) for 20 min and
centrifuged at 14,000 rpm for 20 min at 4 °C in a micro centrifuge.
One hundred and twenty μg of protein lysate were loaded onto a
15% SDS-PAGE mini-gel, transferred to a PVDF membrane and
immunoblotted with monoclonal HPV16 E6 antibody (clone 6F4;
Lagrange et al., 2005) at 5 μg/ml. A goat anti-mouse secondary
antibody conjugated to horseradish peroxidase (Jackson Immunor-
esearch #115-036-071) was used either at 1:10,000 for E6 or at
1:50,000 for β-actin. Detection of E6 or β-actin was achieved by
using the ECL Plus Western Detection Kit for horseradish peroxidase
(Amersham, Piscataway, NJ, USA).
Immunoﬂuorescence detection of HA-tagged E6 variants
NIKS (2×104/ml) were seeded on 8-well Lab-Tek chamber slides
(LAB-TEK® Nalge Nunc Int., Naperville, IL, USA), for immunoﬂuores-
cence. After 48 h NIKS were rinsed with PBS, air-dried, ﬁxed with
methanol at −20 °C for 10 min, air-dried and processed immediately.
Incubation with polyclonal rabbit anti-HA-tag (Y-11, Santa Cruz,
Heidelberg, Germany) was performed at 4 °C overnight followed by
Alexa Fluor 488-donkey anti-rabbit (Molecular Probes, Mississauga,
ON, Canada) (1:400 dilution) for 60min at RT. Each stepwas followed
by three washing steps in cold PBS for 5 min. Finally sections were
rinsed with distilled water, air-dried and mounted in Vectashield
mounting medium (Molecular Probes). For negative control staining,
the primary antibody was omitted. Objects were photographed with
a Nikon eclipse 80i microscope conﬁgured with a Nikon digitalcamera Dxm 1200 to image the NIKS cells with 488 line for green
channel excitation. Exposure time was adjusted and identical for
each image.
Determination of cell cycle
For each E6 genotype and vector alone, 5×105 stably trans-
duced NIKS were plated onto 10 cm Petri dishes and after 24 h
were incubated with 0.5 nM actinomycin D (AD) for 24 h. After
treatment, NIKS were harvested by trypsinization, washed in PBS
and used for cell cycle or Western blot analysis. For cell cycle
analysis, ﬂow cytometry based on the method of Ormerod et al.
(1987) was used. The cellular pellet was re-suspended in 70%
ethanol while vortexing to prevent cell clumps. After ethanol
ﬁxation (30 min at 4 °C), NIKS were rewashed in PBS and ﬁnally
re-suspended in 0.2% Triton X-100/PBS and 250 μg propidium
iodide (PI)/ml PBS. The suspension was then analyzed by ﬂow
cytometry on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ,
USA).
Determination of p53 protein levels by ELISA
After treatment with 0.5 nM AD NIKS were harvested by
trypsinization, counted and 1×105cells/sample used per read-out.
The cells were lysed and remaining levels of p53 were measured by
Diaclone's ready-to-use fully formatted ELISA kit (Diaclone, Besancon,
France). The mean value/STD of 3 independent experiments using
duplicates for each cell line was calculated with Excel.
Organotypic raft cultures and immunoﬂuorescence
Normal human keratinocytes form well differentiated stratiﬁed
squamous epithelia when placed in organotypic culture on collagen
rafts raised to the air–liquid interface (Poumay and Coquette, 2007).
NIKS, like normal keratinocytes, have retained a full differentiation
program. They undergo squamous differentiation when cultivated in
organotypic raft culture as deﬁned by histology (Allen-Hoffmann et
al., 2000). NIKS cells transduced with individual E6 variants or the
prototype as well as NIKS with the empty vector as control were
grown to 70% conﬂuency and 5×106 cells were pipetted on collagen
type I (Curacyte Discovery, Leipzig, Germany) containing primary
ﬁbroblasts. From day 2 on, EGF in the medium was exchanged for
1.88 mM Ca2+. Cultures were harvested after 14 days, ﬁxed for 24 h
in 4% PBS-buffered formaldehyde solution, processed through
different grades of ethanol and embedded in parafﬁn. Five μ
sections on positively charged slides were subjected to antigen
retrieval in 6 mM citrate buffer using a pressure cooker (DAKO,
Mississauga, ON, Canada) according to the manufacturer's recom-
mendations. Antigen double detection was performed with primary
polyclonal rabbit anti cytokeratin 5 (Abcam, Cambridge, MA, USA)
and primary monoclonal mouse anti keratin 10 (DAKO, Mississauga,
ON, Canada) antibodies diluted 1:100 in Chemate antibody diluent
(DAKO, Hamburg, Germany) and incubated overnight at 4 °C. Alexa
Fluor 488 and 594 donkey anti rabbit and mouse antibodies
(Molecular Probes) and diluted 1:800 were used as secondary
reagents. Incubation was stopped after 30 min at room temperature
and slides were mounted in VectaShield mounting medium with
DAPI (Molecular Probes) after 3 washing steps of PBS and 2 ﬁnal
washing steps of distilled water. For negative control staining, the
primary antibodies were omitted. A Nikon eclipse 80i microscope
conﬁgured with a Nikon digital camera Dxm 1200c was used to
image the ﬂuorescent-stained sections with 350, 488 and 594 lines
for blue, green and red channel excitation, respectively. Exposure
times were adjusted to each color channel and identical for each
respective image. Overlays were obtained by using Photoshop CS3
extended.
76 I. Zehbe et al. / Virology 383 (2009) 69–77Quantitative ﬂuorescent analyses
The digital microscopy images were quantiﬁed and the average
ﬂuorescence intensity of each region of interest was calculated using
the Multi Image Quantiﬁcation Analysis System; Cytoview, Petach
Tikva, Israel in the laboratory of Dr. Ilan Tsarfaty, Department of
Human Microbiology at the Sackler School of Medicine (Golan et al.,
2008). All color images from above had been saved in a Tag Image File
Format (TIFF). Four images each of K5 and K10 staining were captured
from different sections and used for quantitative analyses. The regions
of interest, basal and suprabasal, in each imagewere deﬁnedmanually
according to the tissuemorphology of the DAPI stain. These areaswere
deﬁned for each section. To ﬁnally compare the relative levels of
protein expression in each region, the average area intensity valuewas
used.
Induction of apoptosis in semisolid medium
To prepare semisolid medium 3.37 g of methylcellulose was
autoclaved with a magnetic stir bar in a 250 ml bottle, 100 ml of
serum-free medium (Ham's F12 and DMEM at a ratio of 3:1 as well as
Ca2+ at a ﬁnal concentration of 0.66 mM)was heated to 60 °C, added to
methylcellulose, stirred for 20 min at RT followed by adding an
additional 100 ml medium and stirred at 4 °C for 1 h. The semisolid
medium was then centrifuged for 90 min at 10,000 rpm in 50 ml
Falcon tubes to remove non-dissolvedmethylcellulose ﬁbers. Approxi-
mately 2×106 NIKS were plated on 75 cm2 ﬂasks and incubated for
72 h. Medium was changed every 24 h. NIKS were suspended in
semisolid medium at a density of 1×106 cells/ml at 37 °C and 5% C02
atmosphere for 16 h. Negative controls were adherent cells overlaid
with semisolid medium. After incubation in semisolid medium, cells
were washed three times with PBS, washed once in serum-containing
medium and twice in PBS. Pellets were used for the Annexin V-FITC
assay (Sigma) measured by ﬂow cytometry.
Statistical analyses
Data of activity in the various functional assays are presented in the
ﬁgures as average (mean) values+standard deviation (SD). Data were
subjected to one-way ANOVA. Signiﬁcance was accepted at Pb0.05.
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